Pharmafile Logo
Pharmafocus logo
Advanced Search

Boehringer Ingelheim

Showing 15 posts of 111 posts found.

hanmi

Hanmi Pharmaceutical raided over insider trading suspicions

October 17, 2016
Sales and Marketing Boehringer Ingelheim, Genentech, Hanmi Pharmaceutical, south korea

At the end of September, we reported on a busy 24-hour for Hanmi Pharmaceutical, as they secured a deal with …

News
download

Hanmi Pharma shares crash after shock contract termination

September 30, 2016
Manufacturing and Production, Medical Communications, Research and Development Boehringer Ingelheim, Genentech, Germany, HM61713, Hanmi Pharmaceutical, Tagrisso, south korea

News broke on 29 September that Hanmi Pharma, South Korea’s leading drug maker, had signed a $910 million deal with …

News
cancerstudy

Lilly, Boehringer Ingelheim to jointly study combination therapy for breast cancer

July 14, 2016
Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, breast cancer, combination therapy, drug trial

US drug major Eli Lilly (NYSE: LLY) and Boehringer Ingelheim said they will jointly initiate early combination trials in breast cancer. The …

News

Boehringer Ingelheim says Phase III trials for its Ofev slowed progression of fatal lung disease

June 27, 2016
Research and Development, Sales and Marketing Boehringer Ingelheim, drug trial, idiopathic pulmonary fibrosis, research

German drugmaker Boehringer Ingelheim said late-stage trials for its Ofev (nintedanib) to treat a fatal lung condition slowed progression of …

News

Sanofi, Boehringer Ingelheim sign definitive agreements for swap

June 27, 2016
Research and Development, Sales and Marketing Boehringer Ingelheim, Financial, Sanofi, business swap, merger and acquisition

French drugmaker Sanofi (Euronext: SAN) and German pharma firm Boehringer Ingelheim have signed a definitive agreement for a business swap announced …

News
simone_menne

Boehringer Ingelheim names Simone Menne new chief financial officer

June 10, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim

German drugmaker Boehringer Ingelheim has named Simone Menne as its new chief financial officer. The current CFO at Lufthansa will …

Appointment

FDA approves Lilly/Boehringer Ingelheim type-2 diabetes drug

June 1, 2016
Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, FDA, diabetes, jentadueto, jentadueto xr, lilly, partnership, type 2, type-2

The US Food and Drug Administration (FDA) has approved Jentadueto XR (linagliptin and metformin hydrochloride extended release) tablets for the …

News

Nice recommends three drugs to treat diabetes

May 25, 2016
Research and Development, Sales and Marketing AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Janssen, NICE, diabetes

The National Institute for Health and Care Excellence (Nice) has backed three drugs for the treatment of type 2 diabetes. …

News
money_pills_2

Horizon to acquire worldwide rights to Boehringer Ingelheim genetic disease drug

May 20, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, actimmune, agreement, horizon, interferon gamma-1b, worldwide rights

Horizon Pharmaceuticals (NASDAQ: HZNP) has entered into a worldwide rights agreement with Boehringer Ingelheim to acquire interferon gamma-1b, which is …

News
bi_german_building_at_night

Boehringer Ingelheim says new studies underline efficacy of lung disease drug

May 18, 2016
Research and Development, Sales and Marketing Boehringer Ingelheim, lung disease

Boehringer Ingelheim said late-stage trials for its drug to treat chronic lung disease reinstate its efficacy and safety profile. The …

News
jardiance-web

Lilly and Boehringer Ingelheim to evaluate diabetes drug for treatment of heart failure

April 20, 2016
Research and Development Boehringer Ingelheim, Eli Lilly, cardiovascular death, diabetes, heart attack, jardiance, lilly

Eli Lilly (NYSE: LLY) and Boehringer Ingelheim have announced plans to conduct two outcome trials evaluating diabetes medicine Jardiance (empagliflozin) …

News
bi_microparts_image

Boehringer Ingelheim posts 11% rise in FY15 sales boosted by diabetes business

April 20, 2016
Business Services, Research and Development, Sales and Marketing Boehringer Ingelheim, FY, earnings, forecasts, outlook, results

Boehringer Ingelheim reported 11% jump in sales for 2015 driven by its diabetes business and said for 2016 it sees …

News
birdlr

Boehringer Ingelheim’s Giotrif significantly lowers lung cancer progression in Phase II trials

April 13, 2016
Research and Development AstraZeneca, Boehringer Ingelheim, Iressa, giotrif, lung cancer

German drugmaker Boehringer Ingelheim on Wednesday said a mid-stage study has shown its cancer drug Giotrif (afatinib) reduced the risk …

News
handshake

Former US CEO of Boehringer Ingelheim becomes chairman at Inotek Pharmaceuticals

April 11, 2016
Medical Communications Boehringer Ingelheim, inotek, inotek pharma, j martin carroll

Inotek Pharmaceuticals has announced the appointment of J. Martin Carroll as the new chairman of the board. Carroll will succeed …

Appointment
bi_centre_03_2

Boehringer Ingelheim’s Giotrif gets Europan regulatory backing in another lung cancer indication

April 7, 2016
Business Services, Research and Development, Sales and Marketing Boehringer Ingelheim, European Commission, giotrif, lung cancer

German drugmaker Boehringer Ingelheim on Thursday said European regulators have granted marketing rights for its non-small cell lung cancer (NSCLC) …

News

Latest content

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer

May 17, 2024

AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug

May 17, 2024

GSK pledges £45m to Fleming Initiative to fight AMR

May 16, 2024

NeuroSense partners with PhaseV on upcoming phase 3 ALS trial

May 16, 2024

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

May 15, 2024